NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Aims to Halt Cancerous Tumor Progression Utilizing Scorpion Venom Product

Company: PreveCeutical Medical Inc. (PRVCF)
Category: Stock Spotlights

Early-stage life sciences company PreveCeutical Medical’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) novel “scorpion venom” product builds on popular Cuban cancer-fighting therapy. An article discussing the company’s innovative solutions reads: “The scorpion venom product builds on discoveries in Cuba and the surrounding Caribbean nations advancing the popular belief that the venom inhibits the growth of cancer cells. PreveCeutical’s product, CELLB9Ò dietary supplement, utilizes select peptides from the blue scorpion (which is actually red, with a blue tail) to boost the user’s immune system, and the company is advancing its research into producing a “nature identical” scorpion peptide solution that it hopes will be able to not only halt the progress of cancerous tumors, but also treat metabolic disorders, pain, cardiovascular disease and infectious maladies without requiring company representatives to travel to the Caribbean to find and milk the unique scorpions for their naturally produced venom.”

To view the full article, visit http://nnw.fm/vpC1B

About PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com.

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Contact us: 212.418.1217